NOXXON Pharma AG, a developer of mirror image oligonucleotide therapeutics, has closed a EUR 37m series-C financing round. The main investors are TVM Capital, Sofinnova Partners and Edmond de Rothschild Investment Partners. Other investors contributing to this round are Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft, Seventure Partners, Dow Venture Capital, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, VC Fonds Berlin GmbH. The new capital will be used to fund the pre-clinical and clinical development of the company’s lead products in kidney disease and ophthalmology.
Also backing the biotech startup were the Zürcher Kantonalbank and Greencross Medical Science Corp
Company plans to use the fresh capital to further expand, develop new features and scale up its team
EVentures, 468 Capital and HV Holtzbrinck back the round for the climate change mitigation app
Clessidra has been in negotiations for the acquisition of the Italian wine producer since February 2020